SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Status:
RECRUITING
Trial end date:
2027-12-12
Target enrollment:
Participant gender:
Summary
This study was an open-label phase study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.